Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: A systematic review

Haematologica

Volumn 95, Issue 3, 2010, Pages 494-500

  Herbst, Christine ^a   Rehan, Fareed A ^a   Brillant, Corinne ^a   Bohlius, Julia ^b   Skoetz, Nicole ^a   Schulz, Holger ^a   Monsef, Ina ^a   Specht, Lena ^c   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chemotherapy; Combined modality treatment; Hodgkin's lymphoma

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY CANCER; EMBASE; HODGKIN DISEASE; HUMAN; MEDLINE; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE;

COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77949750083     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.015644     Document Type: Review

References (39)

1. Swerdlow, AJ. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2003;30 (Suppl 1):S3-12.
2. Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin's lymphoma. Ann Oncol. 2002;13 (Suppl 4):147-52.
3. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21(19):3601-8.
4. Sasse S, Diehl V Engert A. Combined modality treatment for early-stage Hodgkin's lymphoma: the GHSG experience. Haematologica Reports 2(7);2006.
5. Thomas J, Fermé C, Noordijk EM, van't Veer MB, Brice P, Divine M, et al. Results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favourable or unfavourable early stage Hodgkin's Lymphoma (HL). Haematologica: abstract book 2007;92 (Suppl 5):27.
6. Engert, A., Eichenauer, D. A., and Dreyling, M. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 (Suppl 4).
7. NCCN clinical practice guidelines in oncology. Hodgkin's Disease/Lymphoma V2.2009. www.nccn.org. Last accessed 09/2009
8. Franklin JG, Paus MD, Pluetschow A, and Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database of Systematic Reviews 2005(4):CD003187.
9. Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22(15):3139-48.
10. Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005;23(30):7555-64.
11. Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100(6):2101-8.
12. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a populationbased evaluation over 25 years. J Clin Oncol. 2002;20(16):3484-94.
13. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):1989-96.
14. Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21(23):4386-94.
15. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18(3):487-97.
16. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21(18):3431-9.
17. Green DM, Hyland A, Barcos MP, Reynolds JA, Lee RJ, Hall BC, Zevon MA. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol. 2000;18(7):1492-9.
18. Canellos GP. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol. 20-7-2005;23(21):4574-6.
19. Meyer RM. Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma?. Eur J Haematol 2005;S66:115-20.
20. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, et al. National Cancer Institute of Canada Clinical Trials Group, and Eastern Cooperative Oncology Group. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634-42.
21. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104(12):4383-9.
22. Rehan FA, Bohlius J, Brillant C, Monsef I, Specht L, Engert A. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin Lymphoma [Protocol]. Cochrane Database of Systematic Reviews 2008 (Issue 2):CD007110.
23. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
24. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315(7121):1533-7.
25. The Cochrane Collaboration. The Cochrane Manual Issue 4. http://www.cochrane.org/admin/manual.htm. Last accessed 09/2009
26. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492-5.
27. Aviles A. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease. Clin Lab Haematol. 1998;20(2):95-9.
28. Bloomfield CD, Pajak TF, Glicksman AS, Gottlieb AJ, Coleman M, Nissen NI, et al. Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep. 1982;66(4):835-46.
29. Eghbali H, Brice P, Creemers GY, Marwijk Kooij M, Carde P, Van't Veer MB, et al. Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial. ASH Annual Meeting Abstracts. 2005;106(11):814.
30. Pavlovsky S, Maschio M, Santarelli MT, Muriel FS, Corrado C, Garcia I, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst. 1988;80(18):1466-73.
31. Noordijk EM, Thomas J, Fermé C, Van't Veer MB, Brice P, Divine M, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol 2005 ASCO Annual Meeting Proceedings 2005, 23 (Part I of II):16S.
32. Thomas J, Fermé C, Noordijk EM, Eghbali H, and Henry-Amar M. The EORTC-GELA treatment strategy in clincal stages I-II HL: Results of the H9-F and H9-U trials. International Symposium on Hodgkin Lymphoma, Cologne, Presentation. 2007.
33. Noordijk EM, Thomas J, Fermé C, Van't Veer MB, Brice P, Divine M, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). ASCO Annual Meeting Presentation Slides. 2005.
34. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20(18):3765-71.
35. Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004;22(1):62-8.
36. Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48(9):1721-7.
37. O'Dwyer PJ, Wiernik PH, Stewart MB, Slawson RG. Treatment of early stage Hodgkin's disease: A randomized controlled trial of radiotherapy plus chemotherapy versus chemotherapy alone. In: Cavalli F, Bonadonna G, and Rozencweig M, editors. Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Proceedings of the Second International Conference on Malignant Lymphomas, Lugano, Switzerland, 1984. Bosten: Martinus Nijhoff Publishers;1985, 329-36.
38. Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG, et al. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2006;28(6):362-8.
39. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18(3):498-509.